A high-level overview of Regulus Resources Inc. (RGLSF) stock. View (RGLSF) real-time stock price, chart, news, analysis, analyst reviews and more.

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common stock ...

Novartis today announced that its previously announced tender offer (the "Offer") by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ...

In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for Idorsia's QUVIVIQ in China. Under the ...

Mars and the star Regulus are set to put on a dazzling show tonight as the Red Planet passes remarkably close to Leo’s brightest star in a striking celestial pairing — and you can watch it ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and another interested party raised the stakes several times, a new securitie ...

VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) is pleased to provide an update on the Phase Two ...

Boise and Salt Lake City have both adopted the Pride flag – or a slight variation of it – as official symbols as of Tuesday night, effectively circumventing state law.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

In a deal with total equity value of up to $1.7 billion, a subsidiary of Novartis will merge with Regulus in an offer that is expected to close in the second half of this year.

Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of ...